Multiple events have been reported revolving around
The Cooper Companies, Inc. (NASDAQ:COO). There has been
insider selling indicating potential apprehensions about the company's future. Aberdeen Standard Investments reduced its holdings in the company while Lecap Asset Management and Caprock Group increased their shares. A board member is set to retire in the coming April. The
fundamentals look varied and hence, the clear direction for the stock is uncertain. The
analysts' consensus price target is at $117.00. Q4 earnings reports exceeded Wall Street expectations but the future revenue projections fell short of expectations. Despite this, there have been suggestions to add COO's stock to portfolio. Albert G. White III has been appointed to the board of Evolus, another medical company.
CooperCompanies announced its acquisition of Generate Life Sciences and Cook Medical's reproductive health business. Finally, they also announced organizational management changes. The current bullish or bearish sentiment for the COO stock remains unclear at the moment.
The Cooper Companies COO News Analytics from Wed, 11 Nov 1992 08:00:00 GMT to Sat, 08 Feb 2025 13:59:11 GMT -
Rating 0
- Innovation 0
- Information 3
- Rumor -3
